Outcomes of Pediatric End Stage Renal Disease Patients with Moderate To Severe Covid-19 Infection Who Underwent Hemodialysis With Hemoperfusion In A Tertiary Subspecialty Hospital In Metro Manila: A Retrospective Single Center Study

Outcomes of Pediatric End Stage Renal Disease Patients with Moderate To Severe Covid-19 Infection Who Underwent Hemodialysis With Hemoperfusion In A Tertiary Subspecialty Hospital In Metro Manila: A Retrospective Single Center Study | Research Square window.SnipcartSettings = { analytics: { enabled: false } }; (function() { var accessVector = localStorage.getItem('access_vector') || ''; window.dataLayer = window.dataLayer || []; if (accessVector) { window.dataLayer.push({ user: { profile: { profileInfo: { snid: accessVector } } } }); } })(); (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src='https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);})(window,document,'script','dataLayer','GTM-K279D39R'); Browse Preprints In Review Journals COVID-19 Preprints AJE Video Bytes Research Tools Research Promotion AJE Professional Editing AJE Rubriq About Preprint Platform In Review Editorial Policies Our Team Advisory Board Help Center Sign In Submit a Preprint Cite Share Download PDF Research Article Outcomes of Pediatric End Stage Renal Disease Patients with Moderate To Severe Covid-19 Infection Who Underwent Hemodialysis With Hemoperfusion In A Tertiary Subspecialty Hospital In Metro Manila: A Retrospective Single Center Study Kathrine S Roberto This is a preprint; it has not been peer reviewed by a journal. https://doi.org/ 10.21203/rs.3.rs-3049314/v1 This work is licensed under a CC BY 4.0 License Status: Posted Version 1 posted You are reading this latest preprint version Abstract BACKGROUND SARS-COV 2 became a pandemic in the early part of 2020 affecting individuals of all ages. Patients with End Stage Renal Disease who have COVID-19 infection are at higher risk for morbidity and mortality. There are studies on the use of of hemoperfusion in patients with COVID, however, data on its use in the pediatric population are scarce and conflicting. OBJECTIVE The objective of this study is to determine the clinical outcomes of pediatric end stage renal disease patients with moderate to severe COVID-19 infection who underwent hemodialysis with hemoperfusion in a tertiary subspecialty hospital in Metro Manila METHODS Retrospective cohort study was done. All eligible patients were included in the study. Data collection was conducted through chart review of medical records of ESRD patients <19 years of age admitted at the National Kidney and Transplant Institute from March 1, 2020 to March 1, 2022, presenting with moderate to severe COVID infection. Inflammatory markers and Chest xray were repeated to compare the values from baseline after 1-4 sessions of hemoperfusion. Clinical outcomes were determined in terms of discharge, duration of hospital stay, resolution of symptoms, progression of the severity of COVID infection, and final disposition either death or discharged. RESULTS C-Reactive Protein (CRP), Erythrocyte Sedimentation Rate (ESR), Lactate Dehydrogenase (LDH), and Ferritin decreased after 2-3 sessions of hemodialysis with hemoperfusion but the results were not statistically significant. Procalcitonin significantly decreased after the second session (p=0.046). Pneumonia on Chest xray decreased across all sessions. All patients showed clinical resolution of symptoms and were discharged. CONCLUSION The combined use of hemodialysis and hemoperfusion can be used as adjunct treatment for moderate to severe COVID infection after maximizing supportive and medical management. Should it be employed, 2-3 sessions are safe to improve the patient’s clinical status. Keywords: End Stage Renal Disease, COVID-19 infection, hemoperfusion, inflammatory markers End Stage Renal Disease COVID-19 infection hemoperfusion inflammatory markers Full Text Cite Share Download PDF Status: Posted Version 1 posted You are reading this latest preprint version Research Square lets you share your work early, gain feedback from the community, and start making changes to your manuscript prior to peer review in a journal. As a division of Research Square Company, we’re committed to making research communication faster, fairer, and more useful. We do this by developing innovative software and high quality services for the global research community. Our growing team is made up of researchers and industry professionals working together to solve the most critical problems facing scientific publishing. Also discoverable on Platform About Our Team In Review Editorial Policies Advisory Board Help Center Resources Author Services Accessibility API Access RSS feed Manage Cookie Preferences © Research Square 2026 | ISSN 2693-5015 (online) Privacy Policy Terms of Service Do Not Sell My Personal Information {"props":{"pageProps":{"initialData":{"identity":"rs-3049314","acceptedTermsAndConditions":true,"allowDirectSubmit":true,"archivedVersions":[],"articleType":"Research Article","associatedPublications":[],"authors":[{"id":209298367,"identity":"37d2c910-b86e-460f-b6b1-c672d9f940cc","order_by":0,"name":"Kathrine S Roberto","email":"data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAZAAAAAyAQMAAABI0h/eAAAABlBMVEX///8AAABVwtN+AAAACXBIWXMAAA7EAAAOxAGVKw4bAAABBklEQVRIiWNgGAWjYBACCQYGNgYGAxCTBywgByIOPMCrhRlZSwKDMVhLAkEtDAgtiQ0MYBo3kGw/f+xxRcEdOfP23oOPK3/YpM8PO/wQaIudnG4Ddi3SPMnshmcMnhnLnDmXbHgmIS134+00A6CWZGOzA9i1yDEks0k2GBxOnCGRYybZkHA4d+PsBJCWA4nbcGnhfwzWUg/UYv4TqCXdcHb6B7xapCUgtiRIAG1hBGpJkJfOwW+L5IzHZiAthjN4ziVLNqSlGW6Qzik4kGCA2y8S5xOfSTb8OSwvwd578GODjY28/Oz0zR8+VNjJ4dKCCQzAKg2IVQ4C8g2kqB4Fo2AUjIKRAAAr214uNs3l+AAAAABJRU5ErkJggg==","orcid":"https://orcid.org/0009-0006-7022-2700","institution":"National Kidney and Transplant Institute","correspondingAuthor":true,"submittingAuthor":false,"prefix":"","firstName":"Kathrine","middleName":"S","lastName":"Roberto","suffix":""}],"badges":[],"createdAt":"2023-06-11 13:05:35","currentVersionCode":1,"declarations":"","doi":"10.21203/rs.3.rs-3049314/v1","doiUrl":"https://doi.org/10.21203/rs.3.rs-3049314/v1","draftVersion":[],"editorialEvents":[],"editorialNote":"","failedWorkflow":false,"files":[{"id":38977720,"identity":"9de30118-e7f5-4eff-b6a7-332427896256","added_by":"auto","created_at":"2023-06-23 12:47:49","extension":"pdf","order_by":1,"title":"","display":"","copyAsset":false,"role":"manuscript-pdf","size":375124,"visible":true,"origin":"","legend":"","description":"","filename":"FinalResearchRoberto.pdf","url":"https://assets-eu.researchsquare.com/files/rs-3049314/v1_covered_f26fb7f6-4c42-4923-9824-d143422d66c7.pdf"}],"financialInterests":"","formattedTitle":"\u003cp\u003eOutcomes of Pediatric End Stage Renal Disease Patients with Moderate To Severe Covid-19 Infection Who Underwent Hemodialysis With Hemoperfusion In A Tertiary Subspecialty Hospital In Metro Manila: A Retrospective Single Center Study\u003c/p\u003e","fulltext":[],"fulltextSource":"","fullText":"","funders":[],"hasAdminPriorityOnWorkflow":false,"hasManuscriptDocX":false,"hasOptedInToPreprint":true,"hasPassedJournalQc":"","hasAnyPriority":false,"hideJournal":true,"highlight":"","institution":"","isAcceptedByJournal":false,"isAuthorSuppliedPdf":true,"isDeskRejected":"","isHiddenFromSearch":false,"isInQc":false,"isInWorkflow":false,"isPdf":true,"isPdfUpToDate":true,"isWithdrawnOrRetracted":false,"journal":{"display":true,"email":"[email protected]","identity":"researchsquare","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":true,"externalIdentity":"","sideBox":"","snPcode":"","submissionUrl":"/submission","title":"Research Square","twitterHandle":"researchsquare","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"","reportingPortfolio":"","inReviewEnabled":false,"inReviewRevisionsEnabled":true},"keywords":"End Stage Renal Disease, COVID-19 infection, hemoperfusion, inflammatory markers","lastPublishedDoi":"10.21203/rs.3.rs-3049314/v1","lastPublishedDoiUrl":"https://doi.org/10.21203/rs.3.rs-3049314/v1","license":{"name":"CC BY 4.0","url":"https://creativecommons.org/licenses/by/4.0/"},"manuscriptAbstract":"\u003cp\u003e\u003cstrong\u003eBACKGROUND\u003c/strong\u003e\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eSARS-COV 2 became a pandemic in the early part of 2020 affecting individuals of all ages. Patients with End Stage Renal Disease who have COVID-19 infection are at higher risk for morbidity and mortality. There are studies on the use of of hemoperfusion in patients with COVID, however, data on its use in the pediatric population are scarce and conflicting.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eOBJECTIVE\u003c/strong\u003e\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eThe objective of this study is to determine the clinical outcomes of pediatric end stage renal disease patients with moderate to severe COVID-19 infection who underwent hemodialysis with hemoperfusion in a tertiary subspecialty hospital in Metro Manila\u0026nbsp;\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eMETHODS\u003c/strong\u003e\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eRetrospective cohort study was done. All eligible patients were included in the study. Data collection was conducted through chart review of medical records of ESRD patients \u0026lt;19 years of age admitted at the National Kidney and Transplant Institute from March 1, 2020 to March 1, 2022, presenting with moderate to severe COVID infection. Inflammatory markers and Chest xray were repeated to compare the values from baseline after 1-4 sessions of hemoperfusion. Clinical outcomes were determined in terms of discharge, duration of hospital stay, resolution of symptoms, progression of the severity of COVID infection, and final disposition either death or discharged.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eRESULTS\u003c/strong\u003e\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eC-Reactive Protein (CRP), Erythrocyte Sedimentation Rate (ESR), Lactate Dehydrogenase (LDH), and Ferritin decreased after 2-3 sessions of hemodialysis with hemoperfusion but the results were not statistically significant. Procalcitonin significantly decreased after the second session (p=0.046). Pneumonia on Chest xray decreased across all sessions. All patients showed clinical resolution of symptoms and were discharged.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONCLUSION\u003c/strong\u003e\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eThe combined use of hemodialysis and hemoperfusion can be used as adjunct treatment for moderate to severe COVID infection after maximizing supportive and medical management. Should it be employed, 2-3 sessions are safe to improve the patient’s clinical status. \u0026nbsp; Keywords: End Stage Renal Disease, COVID-19 infection, hemoperfusion, inflammatory markers\u003c/p\u003e","manuscriptTitle":"Outcomes of Pediatric End Stage Renal Disease Patients with Moderate To Severe Covid-19 Infection Who Underwent Hemodialysis With Hemoperfusion In A Tertiary Subspecialty Hospital In Metro Manila: A Retrospective Single Center Study","msid":"","msnumber":"","nonDraftVersions":[{"code":1,"date":"2023-06-15 02:05:32","doi":"10.21203/rs.3.rs-3049314/v1","editorialEvents":[{"type":"communityComments","content":0}],"status":"published","journal":{"display":true,"email":"[email protected]","identity":"researchsquare","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":true,"externalIdentity":"","sideBox":"","snPcode":"","submissionUrl":"/submission","title":"Research Square","twitterHandle":"researchsquare","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"","reportingPortfolio":"","inReviewEnabled":false,"inReviewRevisionsEnabled":true}}],"origin":"","ownerIdentity":"376b7704-de60-4c78-a328-5c96c80664b6","owner":[],"postedDate":"June 15th, 2023","published":true,"recentEditorialEvents":[],"rejectedJournal":[],"revision":"","amendment":"","status":"posted","subjectAreas":[],"tags":[],"updatedAt":"2023-06-23T12:47:22+00:00","versionOfRecord":[],"versionCreatedAt":"2023-06-15 02:05:32","video":"","vorDoi":"","vorDoiUrl":"","workflowStages":[]},"version":"v1","identity":"rs-3049314","journalConfig":"researchsquare"},"__N_SSP":true},"page":"/article/[identity]/[[...version]]","query":{"redirect":"/article/rs-3049314","identity":"rs-3049314","version":["v1"]},"buildId":"FbvkV6FR0MCFSLy54lSbu","isFallback":false,"isExperimentalCompile":false,"dynamicIds":[84888],"gssp":true,"scriptLoader":[]}